LAGUNA HILLS, Calif., Feb. 06, 2017 -- Sonendo® Inc. today announced it has acquired PIPStek™ LLC, including all of the intellectual property for its PIPS® laser technologies. PIPStek™ LLC will continue as a stand-alone company and will be a wholly owned subsidiary of Sonendo.
Sonendo’s GentleWave® System will continue to be Sonendo’s only offering for root canal therapy. Sonendo will not be commercializing a PIPS® - based therapy for endodontics. Studies have shown that the GentleWave Procedure shows significant improvement in clinical efficacy and treatment efficiency when compared to standard root canal treatments1-2.
Commenting on the transaction, Bjarne Bergheim, President and Chief Executive Officer of Sonendo, stated, “We are excited about this acquisition and the road ahead. PIPStekTM and PIPS® technologies will help pave the way for other opportunities in dentistry beyond endodontics. We are also excited that Dr. Enrico DiVito will be joining the Sonendo team to support our customers, and help us develop technologies for other areas in dentistry that improve clinical efficacy and treatment efficiency.”
“Bjarne and I share a common passion for developing transformative technologies for the dental profession that improve patient outcomes and I look forward to joining the Sonendo team. Just like Bjarne, I too share Sonendo’s mission of Saving Teeth Through Sound Science®,” said Dr. Enrico DiVito DDS, former CEO of PIPStekTM.
About Sonendo
Sonendo, Inc. is a privately-held, venture-backed company developing innovative and disruptive technologies to transform dentistry by Saving Teeth Through Sound Science. The first commercially available product from Sonendo, the GentleWave System, available in the US, shows significant improvements in clinical efficacy, and treatment efficiency when compared to standard root canal techniques1-2. For more information please visit: www.sonendo.com.
1Sigurdsson A et al. (2016) J Endod. 42:1040-48. 2Molina B et al. (2015) J Endod. 41:1701-05.
Forward-Looking Statements
This announcement contains forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that address events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to the timing and progress of research and development activities. Management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made. Sonendo does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.
Media Contact: Bob Guyatt Vice President of Marketing 949.766.3636


Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 



